NEW YORK (GenomeWeb) – Guardant Health today announced that it has partnered with the National Cancer Institute-funded SWOG cancer research consortium to identify mechanisms of resistance and future treatment options in non-small cell lung cancer patients.

The study, called SWOG-1403, will use Guardant's circulating tumor DNA test, Guardant 360, to examine whether combination EGFR blockade using cetuximab and afatinib is superior to afatinib alone as a frontline treatment for 600 patients with newly diagnosed EGFR-mutant NSCLC.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.

Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.

In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.